ZOVOO
10.12.2021 09:28:14 CET | Business Wire | Press release
ZOVOO , founded in 2019 and emerging as a dark horse in the electronic cigarette industry, recently launched its latest product Dragbar and achieved a sales milestone of over 1,000,000 pieces in the global market in less than one month, fully demonstrating the extraordinary strength of ZOVOO .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211210005123/en/
User-oriented and differentiated to meet market demand
According to ZOVOO' s global sales analysis, ZOVOO had an impressive performance in Southeast Asia, North America and Europe, which is attributable to not only Dragbar' s excellent capability, but also the ZOVOO team's in-depth and detailed market analysis of different regions.
Dragbar' s innovation and research team employed polymer fibers and ergonomic lip sensation design to address the consumers' most-concerned issues such as oil leakage and dry hit, while also ensuring the taste and recovery of the product. Using the most popular double injection molding process and the collision of extremely vibrant colors, the high-quality product is aesthetically attractive and tasteful, and soon gained the recognition of the consumers.
Product preference varies in different markets, so the team made in-depth investigations on product appearances and sizes and provided different series of Dragbar to cater to users in different regions, eventually achieving sales performance that was in line with the target of the ZOVOO team.
Creating amazing products with extreme craftsmanship
The ZOVOO design team, with its decade-long history, consists of senior creative elites, concept artists, visual designers and technical engineers. As ZOVOO 's first product for the overseas market, Dragbar cost the design team a whole year to finish. Even after thousands of adjustments, tests, and appearance improvements, the team did not start mass production until it was 100% confident with the final product.
In addition, since the founding of ZOVOO , the team has been focused on technology, constantly making breakthroughs and pursuing new patents and new technologies. During the long process ranging from research and development to design, production, and testing before the launch of each product, the innovation and research team is particular about every detail of the product, so as to bring comfortable and safe experience to the consumers.
Dragbar' s sales volume of 1,000,000 pieces achieved in a short period of time fully demonstrated the ZOVOO team's accurate insight into the users' needs, its excellent research and development capabilities, as well as its forward-looking product design strength. With the excellent performance of Dragbar, ZOVOO has successfully entered markets in more than 50 countries and regions in North America, Europe and Southeast Asia. In the future, the ZOVOO team will continue to develop new products in line with market trends to meet the users' new needs.
About ZOVOO
ZOVOO has established strategic partnerships with ICCPP manufacturers on a basis of mutual trust. ZOVOO enables its sustainable supply chain management by supporting safety standards, social values and environment-friendliness. With the motto of "Creating is Endless", ZOVOO is committed to adding inspirations to the colorful life of people with technology, and seeking partners globally to better serve the consumers.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical. The product is only intended for adult smokers of legal purchase age.
ZOVOO Official Website: https://www.izovoo.com/
IG: https://www.instagram.com/zovoo_tech/
Facebook: https://www.facebook.com/zovootechofficial
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211210005123/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wyss Geneva Steps Into Its Next Chapter11.6.2026 13:33:00 CEST | Press release
Dr. Tracy Laabs named Director; Prof. Dr. Erwin Böttinger honored for his transformative leadership The Wyss Center for Bio and Neuroengineering in Geneva is pleased to announce the appointment of Dr. Tracy Laabs as Director, effective July 1st 2026. Dr. Laabs succeeds Prof. Dr. Erwin Böttinger, who leaves behind a fundamentally transformed organization: one that no longer just pursues breakthrough science but systematically turns it into ventures that reach patients. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260611328520/en/ Dr. Tracy Laabs, incoming Director, Wyss Center Geneva Since joining the Wyss Center as Director in April 2023, Prof. Böttinger brought a bold vision: to evolve the Center from a portfolio of promising projects into a disciplined engine for venture creation. Under his leadership, the Center spun off six companies in two years (including ABILITY Neurotech SA and Clee Medical SA in 2025) while simult
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit11.6.2026 13:24:00 CEST | Press release
Nearly two-thirds of patients aged 80+ treated with BRUKINSA remained progression-free at six years, despite advanced age and high-risk featuresNew European patient research reveals safety, disease severity, and effectiveness are the top drivers for first-line CLL treatment decisions – not time on therapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced the presentation of a large Phase 3 dataset in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) aged 80 and older, showing sustained benefit with BRUKINSA after nearly 6.5 years of follow-up, reinforcing its role as the foundational BTK inhibitor. BRUKINSA is the only BTK inhibitor to demonstrate superior efficacy vs. ibrutinib in a Phase 3 trial.1 These data, one of the largest datasets of older patients with treatment-naive CLL, will be presented at the 2026 European Hematology Association (EHA) Congress in Stockholm, Sweden. Amit Agarwal, M.D.,
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations11.6.2026 13:00:00 CEST | Press release
Once-daily oral zasocitinib demonstrated statistical superiority over deucravacitinib for all primary and key secondary endpoints in plaque psoriasis study More than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100) at week 16 – more than 2.5 times the response rate for deucravacitinib Safety profile was consistent with previous studies with no new safety signals identified Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority over deucravacitinib for the primary endpoint, Psoriasis Area and Severity Index (PASI) 100 response rate at week 16. The study also demonstrate
Clearlake Expands Liquid Credit Platform With Acquisition of LCM Asset Management’s CLO Contracts11.6.2026 13:00:00 CEST | Press release
Transaction adds 31 CLOs and more than $5 billion of AUM, strengthening Clearlake Credit’s position in liquid credit Clearlake Capital Group, L.P. (“Clearlake” or the “Firm”), a global investment firm managing integrated platforms spanning private equity, liquid and private credit, and other related strategies, today announced that its credit platform, Clearlake Credit, will assume management of CLOs managed by LCM Asset Management, LLC. The transaction adds 31 CLOs representing more than $5 billion of assets under management and increases assets managed by Clearlake Credit to approximately $39 billion across liquid credit, private credit, and other customized credit solutions. The acquisition further broadens the Firm’s capabilities, deepens its relationships with institutional investors, and reinforces its client-centric approach and commitment to seeking attractive risk-adjusted returns across market cycles. Milbank LLP and Dechert LLP represented Clearlake Credit in the transaction
L&T Technology Services, Databricks Partner to Deliver Industrial AI at Scale for Asset-Intensive Industries11.6.2026 12:30:00 CEST | Press release
Partnership brings together LTTS’ expertise in its Sustainability segment and the Databricks platform to accelerate Engineering Intelligence across industrial operations. L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in AI, Digital & ER&D Consulting Services, today announced a strategic go-to-market partnership with Databricks, the leading Data and AI company, to co-develop and deliver Industrial AI solutions that advance Engineering Intelligence (EI) for asset-intensive enterprises. Anchored in LTTS' Sustainability segment, spanning Process Engineering, Discrete Manufacturing and Industrial Products, the partnership will support Energy, Petrochemicals and Industrials clients globally. As industrial organizations seek to unlock greater value from decades of operational and engineering data, the alliance will combine LTTS’ deep domain capabilities with the Databricks platform to transform complex plant data into Engineering Intelligence - enabling improved asset reli
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom